BioMark Diagnostics Inc. will participate in two major life sciences events in Quebec in October 2026: the MSACL 2026 conference and the inaugural BIOHorizon 2026. The company will highlight its metabolomics-based liquid biopsy technology for early lung cancer detection, engaging with clinical mass spectrometry experts and healthcare stakeholders. BioMark aims to expand its laboratory testing and partnerships as it advances its lung cancer screening panel toward regulatory approval and clinical use. This presence supports ongoing growth at its Quebec City lab, which is increasing its testing capacity and validation efforts.
BioMark Diagnostics Inc.'s upcoming participation in MSACL 2026 and BIOHorizon 2026 life sciences conferences provides context for readers interested in health sector developments. For readers following health stocks, here is Pluang's market snapshot as of Sep 21, 2026 18:51 WIB: Among 95 priced US health-sector stocks tradable on Pluang, 55 rose and 26 fell today. Notable movers include AbCellera Biologics Inc (ABCL) at USD 12.88 with a 1-day change of +1.98% and a typical hold time of 40 days, Abeona Therapeutics Inc (ABEO) at USD 5.46 with a -1.97% change and 22 days hold time, and Ginkgo Bioworks Holdings Inc (DNA) at USD 8.03 with a +1.90% change and 11 days hold time.
On September 21, 2026, Sandisk was added to the S&P 100 index, replacing Nike, which was removed on the same day. This change reflects shifts in market capitalization and company performance within the index. The update is significant for investors t...
Several top analysts, including Cantor Fitzgerald, Guggenheim, Morgan Stanley, and BTIG Research, have raised price targets and upgraded their outlooks for ServiceNow, signaling confidence in the company's long-term growth. Despite this, the stock ha...
Piper Sandler lowered Colgate-Palmolive's price target to $95 due to weak North American demand and rising competition. The company is responding by focusing on premium oral care innovations, expanding the Fabuloso line, increasing advertising, and c...
MillerKnoll is set to report Q3 2026 earnings with analysts expecting $0.35 EPS and $940.93 million in revenue. The North America Contract segment shows strength with higher prices and volumes, while the Global Retail segment struggles due to tariffs...
Rothschild & Co Redburn raised Microsoft's price target from $400 to $440 following strong fiscal 2026 results, with revenue up 18% to $331.8 billion and net income rising 31% to $133.7 billion, driven by cloud and AI demand. Despite the target hike,...
